SCM
CRBP icon

Stonepine Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Stonepine Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.6M Sell
383,462
-6,454
-2% -$54.3K 1.44% 12
2025
Q4 		$3.17M Buy
+389,916
New +$4.81M 2.32% 9
2025
Q2 		– Sell
-35,000
Closed -$186K – 64
2025
Q1 		$186K Buy
+35,000
New +$309K 0.18% 52

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Stonepine Capital Management's CRBP Position: Q1 2026 in Review

Stonepine Capital Management reduced its Corbus Pharmaceuticals (CRBP) stake by 1.7% in Q1 2026, selling an estimated $54.3K and leaving 383,462 shares worth $3.6M. The position accounts for 1.44% of the portfolio, ranked #12.

Stonepine Capital Management first reported a position in CRBP in Q1 2025 and has held it in 3 quarters since. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Stonepine Capital Management held 383,462 shares of Corbus Pharmaceuticals worth $3.6M as of Q1 2026.
  • Stonepine Capital Management sold 6,454 Corbus Pharmaceuticals shares in Q1 2026, an estimated $54.3K.
  • Corbus Pharmaceuticals made up 1.44% of Stonepine Capital Management's portfolio in Q1 2026, its #12 holding.
  • Stonepine Capital Management first reported a position in Corbus Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.